Viridian Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viridian Therapeutics, Inc. (Nasdaq: VRDN) on July 14, 2021. The report discloses a corporate governance change involving the appointment of a new director and Audit Committee Chair.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and associated compensation.
Material Changes
On July 14, 2021, the Board of Directors appointed Jennifer K. Moses as a Class II director and Chair of the Audit Committee, effective immediately. Her term will last until the 2023 Annual Meeting of Stockholders or until a successor is elected.
Management Commentary and Compensation Details
- Compensation: Ms. Moses will receive an annual cash retainer of $55,000 for her service as a Board member and Audit Committee Chair.
- Equity Grant: She was granted an option to purchase 25,000 shares of common stock at the closing price on July 14, 2021.
- Vesting Schedule: The equity award vests in equal monthly installments over a three-year period, contingent on continued service.
- Background: Ms. Moses is a CPA with prior experience as CFO of G1 Therapeutics, Inc. and as a partner at Rankin McKenzie, LLC.
Investor Verification Checklist
- Verify the closing stock price on July 14, 2021, to determine the exercise price of the 25,000 share option grant.
- Review the Company's 2016 Amended and Restated Equity Incentive Plan for terms regarding the equity award.
- Confirm the total number of authorized shares and outstanding options under the equity plan to assess dilution impact.
- Check the Company's Proxy Statement on Schedule 14A (filed April 30, 2021) for the full non-employee director compensation policy.